Document is current
Any future updates will be listed below
-
Authors
Fuggle, Nicholas R. https://orcid.org/0000-0001-5463-2255
Chapurlat, Roland
Laslop, Andrea https://orcid.org/0009-0009-2707-3959
Al-Daghri, Nasser
Alokail, Majed
Thiyagarajan, Jotheeswaran Amuthavalli
Balkowiec-Iskra, Ewa https://orcid.org/0000-0001-8882-9769
Berenbaum, Francis https://orcid.org/0000-0001-8252-7815
Bemden, Angie Botto-van
Borg, John-Joseph
Bruyère, Olivier
Burlet, Nansa
Cavalier, Etienne
Rosa, Mario M. https://orcid.org/0000-0003-3158-2106
Conaghan, Philip G. https://orcid.org/0000-0002-3478-5665
Cooper, Cyrus https://orcid.org/0000-0003-3510-0709
Dennison, Elaine M.
Englund, Martin https://orcid.org/0000-0003-3320-2437
Im, Gun-il
Haugen, Ida K.
Hiligsmann, Mickaël
Kurth, Andreas
Lane, Nancy https://orcid.org/0000-0002-0177-2198
Lories, Rik
Marlovits, Stefan
Matijevic, Radmila
Mobasheri, Ali https://orcid.org/0000-0001-6261-1286
Ormarsdóttir, Sif
Yerro, Maria C. Prieto
Radermecker, Régis P.
Rannou, François
Sepodes, Bruno
Silverman, Stuart
Torre, Carla
Veronese, Nicola https://orcid.org/0000-0002-9328-289X
Rizzoli, René https://orcid.org/0000-0002-1537-422X
Reginster, Jean-Yves
Harvey, Nicholas C. https://orcid.org/0000-0002-8194-2512
- License Information
-
More Information
Article History
Accepted: 5 September 2025
First Online: 3 October 2025
Competing interests
: R.C., N.A-D., M.A., J.A.T., J.-J.B., N.B., E.C., M.M.R, C.C., G.I.I., A.K., N.L., S.M., R.M., S.O., M.C.P.Y., R.P.R., F.R., B.S., S.S., C.T., A.L. and E.B.I. declare no competing interests. N.R.F. has received speaker fees and honoraria from UCB and Viatris and travel bursaries from Pfizer and Eli Lilly. F.B. reports personal fees from 4 P Pharma, 4Moving Biotech, Grunenthal, GSK, Heel, Nordic Bioscience, Novartis, Servier, TRB Chemedica and Viatris. O.B. has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris. P.G.C. has performed consultancies or speakers bureaus for Eli Lilly, Eupraxia, Formation Bio, Galapagos, Genascence, GSK, Grunenthal, Janssen, Kolon TissueGene, Levicept, Medipost, Moebius, Novartis, Pacira, Sandoz and Stryker & Takeda. E.M.D. reports honoraria from UCB, Viatris and Pfizer. M.E. reports consultancy for Grünenthal Sweden AB and Key2Compliance. I.K.H. reports personal fees from Novartis, AbbVie, Grünenthal and GSK during the past 36 months. M.H. reports in the past 36 months research grants (paid to institution) from Radius Heath and Angelini Pharma, as well as lecture or consulting fees (all paid to institution) from Grunenthal, Pfizer, Mylan Pharmaceuticals and IBSA. Leuven R&D and the valorization division of KU Leuven, and has received speaker fees and honoraria from AbbVie, Amgen, Galapagos, Biosplice (formerly Samumed), Biocon (formerly Viatris), Eli-Lilly, Novartis and UCB on behalf of R.L. A.M. has received speaker fees and honoraria from HALEON, Grünenthal, Kolon TissueGene, Kolon Life Science Cluster, Aptissen SA, California Institute for Regenerative Medicine (CIRM), Sanofi, Sanofi Consumer Healthcare, GSK, Novartis, Pfizer, Viatris, Contura, Enlivex, Orion Corporation, Pluri, Pacira Biosciences, Laboratoires Expanscience and Synartro Ampio Pharmaceuticals. N.V. reports personal fees from IBSA, Mylan, Viatris, Sanofi, Nestlè and Fidia outside of the submitted work. R.R. has received fees for advisory board or lectures from Abiogen, Effryx and Theramex. J-Y.R. reports consulting fees or paid advisory boards for IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer and Mithra Pharmaceuticals, lecture fees when speaking at the invitation of sponsor for IBSA-Genevrier, Mylan, Cniel, Dairy Research Council, Nutricia, Danone and Agnovos, and grant support from IBSA-Genevrier, Mylan, Cniel, Radius Health and TRB. N.C.H reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex and Internis Pharma.
